Pediatric cancer research: Surviving COVID-19

Jeffery J. Auletta1,2,3,4 | Peter C. Adamson5 | Jonathan E. Agin6 | Pamela Kearns7,8 | Scott Kennedy9 | Mark W. Kieran10 | Donna M. Ludwinski9 | Leona J. Knox11 | Kristi McKay9 | Pia Rhiner9 | Carol J. Thiele12 | Timothy P. Cripe1,3,4

1Division of Pediatric Hematology/Oncology/BMT, Nationwide Children’s Hospital, Columbus, Ohio
2Division of Infectious Diseases, Nationwide Children’s Hospital, Columbus, Ohio
3Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio
4The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
5Oncology Development & Pediatric Innovation, Sanofi, Cambridge, Massachusetts
6Max Cure Foundation, New York, New York
7European Society of Paediatric Oncology, Brussels, Belgium
8Cancer Research UK Clinical Trials Unit, National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Sciences, Birmingham, UK
9Solving Kids’ Cancer, New York, New York
10Bristol Myers Squibb, New York, New York
11Solving Kids’ Cancer, London, UK
12Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

Correspondence
Jeffery J. Auletta, Division of Pediatric Hematology/Oncology/BMT, Nationwide Children’s Hospital, 700 Children’s Drive, Suite 5A.1, Columbus, OH 43205. Email: jeffery.auletta@nationwidechildrens.org

Abstract
A diverse panel of pediatric cancer advocates and experts, whose collective experience spans the continuum of international academic medicine, industry, government research, and cancer advocacy, recently discussed challenges for pediatric cancer research in the context of coronavirus disease 2019 (COVID-19). Specifically, this special report addresses the following focus areas: (a) the critical role that translational research has played in transforming pediatric cancer outcomes; (b) the current and potential future impact of COVID-19 on pediatric cancer research; (c) target areas of COVID-19 research that may have application in immunity, oncogenesis, and therapeutic discovery; and (d) future considerations and directions in maintaining pediatric cancer research during and after COVID-19.

KEYWORDS
advocacy, cancer, coronavirus, COVID-19, inflammation, pediatrics, relapse, research, systemic acute respiratory syndrome, tumor

1 | INTRODUCTION

Stakeholders in pediatric cancer care and research, including academic physicians, basic science researchers, and leaders in pediatric cancer drug development, consortia, and advocacy groups, recently participated in a webinar on April 28, 2020 entitled “The Pandemic’s Impact on the Pediatric Cancer Research Landscape.” The purpose of the webinar was to discuss the impact of coronavirus disease 2019 (COVID-19) on pediatric cancer care and research. Topics pertinent to current and future directions for pediatric cancer care and research are summarized in this special report.

1.1 | Improving patient outcomes in pediatric cancer: The critical role for translational research

Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis for children with
| Challenges | Potential reason(s) | Potential consequence(s) |
|------------|--------------------|--------------------------|
| **Workforce related** | | |
| Reduced clinical research workforce | Contract COVID-19 | Delay in patient recruitment |
| | Reduced staff (furloughs, job loss) | Delays data collection and submission |
| | Work from home mandates | Potential compromise in data quality |
| Reduced laboratory research workforce | Contract COVID-19 | Little to no laboratory research being performed beyond “essential” |
| | Reduced staff (furloughs, job loss) | Delays in publications, grant submissions, report deadlines due to incomplete data |
| | Work from home mandates | Delayed or compromised training of future workforce |
| | Exclusion of trainees due to social distancing | |
| Reduced capacity of institutional review board | Reduced staff (furloughs, job loss) | Deferred or prolonged new protocol review |
| | Work from home mandates | Prolonged review of protocol amendments |
| | More protocol amendments | |
| | Influx of COVID-19-related protocols | |
| On-site monitoring suspended | Sponsor (furloughs, job loss, work from home mandates) | Reduced interaction with sponsor |
| Consent process by phone | Phone consent | Compromised patient understanding especially low socioeconomic status patients |

| Research | | |
|----------|-----------------|------------------|
| Observational research (natural history) | Deemed nonessential | Gaps in registry patient data |
| Biorepository databases | Deemed nonessential | Less patient biospecimens |
| Phase I and II trials | Suspended | Less treatment options for patients with relapsed, refractory disease |
| Reduced clinical revenue from hospital | Decreased patient volumes | Furloughed or permanent loss of clinical research workforce |

| Funding | | |
|---------|-----------------|------------------|
| Institutional | Reduced patient care volumes, budget | Slower discovery and delayed impact on patients |
| Government | Limited or reallocated resources | Slower discovery and delayed impact on patients |
| Philanthropic | Reduced funding due to lower donations | Slower discovery and delayed impact on patients |

Cancer has improved dramatically. The 5-year survival rate for childhood cancers, many of which were uniformly fatal in the prechemotherapy era, is now approaching 80%. Significant improvements in outcomes for pediatric cancers are the result of enhanced understanding of disease biology, successful application of disease risk stratification, and improved therapeutic approaches including use of multiagent chemotherapy or multimodality therapies. Despite these advances, several childhood cancers still have unacceptably low cure rates, and even when treatment is successful, the acute and long-term morbidity and mortality of current therapy can be substantial.

Central to the continuous improvement in outcome for children with cancer have been collaborative clinical-translational research efforts throughout the world. In fact, pediatric oncology as a clinical and academic subspecialty evolved in tandem with improvements in cancer outcomes for children. As cancer continues to be the leading cause of death from disease in children, it is imperative that these research efforts continue and the infrastructure supporting such research be maintained in both the near and long term.

### 1.2 COVID-19: Current impact on pediatric oncology care and research

As of May 6, 2020, the COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has reached over 3.5 million cases and over 245,000 deaths globally. The pandemic has caused healthcare capacities to be exceeded in many countries, most notably in China, Italy, Spain, the United Kingdom, and the United States. As a result, healthcare workers and associated hospital staff have been challenged with depleting basic care necessities for themselves and their patients. In addition, routine patient care, including preventative care such as vaccination administration and well-child care, has been disrupted.

Beyond the devastating toll on human life and the healthcare systems, COVID-19 has caused severe economic disruption, negatively impacting the way of life for millions through necessary social isolation and work from home policies as well as indefinite job furloughs or even permanent job loss. Millions of people have been confronted...
with difficulties in providing for themselves, their families, or their employees. Healthcare systems have not been immune to negative budget effects, especially pediatric hospitals that have seen a shift to focus on COVID-19 and lower patient volumes for routine and elective care resulting in revenue loss and need for mandated worker furloughs.

Yet most pediatric hematologic/oncology and transplant care continues, albeit with some modifications, including deferrals of off-therapy visits and imaging, long-term/survivorship follow-up visits, nonessential transplants, as well as the use of telemedicine to replace nonurgent follow-up appointments. In contrast, patients with new hematologic or malignant diagnoses and those on-therapy patients appear to be receiving necessary therapies, including hematopoietic cell transplants. This experience differs from adult cancer care, which has been modified substantially given the burden of severe COVID-19 in adult patients.6

In contrast to maintaining continuity in clinical pediatric cancer care, pediatric cancer research has been significantly interrupted by the COVID-19 pandemic. Interruptions in research include disruptions in both clinical and basic science research, performance of only essential laboratory research, limited or deferred opening of new intervention and nonintervention clinical trials, delayed or deferred data collection and reporting, and reduced revenue to support research (Table 1).

Support from patient advocacy groups and charitable organizations are critical to pediatric cancer research, given the comparatively low levels of government funding earmarked for pediatric cancer research.

### TABLE 2 Challenges for pediatric cancer advocacy and funding groups during the COVID-19 pandemic

| Challenge | Potential reason(s) | Potential consequence(s) |
|-----------|--------------------|-------------------------|
| Reduced financial support/philanthropy | Limited donations given personal budget constraints or loss of revenues from in person event cancellations and economic uncertainties | Less resources to offer patients and families, less funding for treatment and nontreatment related expenses New programs delayed or canceled Grant opportunities reduced, delayed or canceled |
| New patients not recruited to sponsored clinical trials | Resources diverted to COVID-19 | Increased anxiety and fear among patients and families Reduced options for treatment of relapsed/refractory disease, potential reduction in overall survival |
| Sponsored programs delayed or canceled | Research and development resources diverted Research labs closed Workers furloughed | Pressure from donors and supporters to move programs forward Unanticipated additional costs |
| Reduced community engagement | Community focus on COVID-19 | Reduced philanthropy |
| Limitations in available housing and transportation | Restrictions in place from COVID-19 | Impact on clinical care |
| Reduced lobbying for pediatric cancer | Government focus on COVID-19 | Less government awareness and earmarked funding |
| National and international pediatric oncology meetings canceled or postponed | Missed opportunities for engagement with other stakeholders | Collaborative partnerships not developed |

### TABLE 3 Industry challenges due to COVID-19

| Challenge | Potential reason(s) | Potential consequence(s) |
|-----------|--------------------|-------------------------|
| Reduced financial support | Limited budgets | Less discovery of novel molecules |
| Reduced clinical research workforce | Contract COVID-19 Reduced staff (furloughs, job loss) Work from home mandates | Delay in recruitment Delays in data collection and submission Potential compromise in data quality |
| Reduced laboratory workforce | Contract COVID-19 Reduced staff (furloughs, job loss) Work from home mandates Exclusion of trainees due to social distancing | Little to no laboratory research being performed beyond “essential” Delays in publications, report deadlines due to incomplete data Delayed or compromised training of future workforce |
| Reallocation of resources | Shifting portfolios to COVID-19 | Less discovery, less clinical trials in oncology |
| Implementation of novel therapeutics | Deferring trials involving agents that suppress immune system, increase susceptibly to COVID-19 Minimizing therapy-related risk to the patient | Less discovery, less clinical trials in oncology, less enrollment of eligible patients |
TABLE 4 Potential new directions for cancer research related to COVID-19

| Focus | Potential benefit(s) |
|-------|----------------------|
| **Basic science** | |
| Immune response to SARS-CoV-2 | Define immune pathways and define antibody induction and duration to redirect new knowledge toward understanding and implementing immunotherapies for pediatric cancer |
| ACE2 receptor | Explore role in lung metastases and increased understanding for tumor immunology |
| | |
| Endothelial cell activation | COVID-19-related microangiopathy and thrombosis and increased understanding for vascular metastasis and thrombosis |
| **Clinical research** | |
| Biorepository | Collect samples prospectively, analyze retrospectively and define mechanism of action and biologic effects as new diagnostics and therapies advance |
| Repurposing cancer therapeutics | |
| Data collection on cancer patients with and without COVID-19 | Define influence of COVID-19 on cancer outcomes and SARS-CoV-2 and risk for childhood malignancies |
| Epidemiology studies | |

Examples of support from advocacy groups include financial support for new research via grant funding, resources for patients and families to engage in clinical trials such as providing financial support for housing and transportation, patient and family education, and government advocacy at the local and national levels. Challenges during COVID-19 for patient advocacy groups and the charity sector include limited resources for patients and families mainly due to dramatically reduced philanthropic support, but also due to social restrictions affecting patient movement and lodging; reduced community engagement given direct effects of the pandemic on donor finances and health; and less government advocacy impact given its focus on the pandemic and its reallocating resources to address the pandemic (Table 2).

Importantly, industry has a vital role in supporting pediatric cancer research through drug discovery, laboratory research, and codevelopment of and support for clinical trials. Current challenges faced by industry include reduced available workforce, reallocation of resources to focus on assessment of pipelines for agents with potential value for COVID-19 patients, and contracted budgets for drug discovery (Table 3).

Taken together, COVID-19-related challenges among academic institutions, advocacy groups, and pharmaceutical industries are significant. How profound the impact these challenges will have on pediatric oncology research will be determined by several factors: sustained prevalence of COVID-19 determined by availability of point-of-care viral screening and serologic testing as well as vaccine development; favorable risk-benefits for loosening social restrictions that currently limit research as well as impact patients and families; availability of laboratory reagents and clinical therapies as determined by supply line disruptions; and availability of funding and resources at the institutional, government, and philanthropic levels based upon recovery of global and local economies.

1.3 | COVID-19: Focus on pediatrics and the immune response to SARS-CoV-2

Significant morbidity and mortality secondary to COVID-19 infection have largely spared the pediatric population, including pediatric hematology, oncology, and hematopoietic cell transplant patients. In general, immunocompetent pediatric patients with COVID-19 experience less severe disease than adult patients, particularly adults with comorbidities such as cardiovascular disease, chronic lung disease, and diabetes. Children identified at higher risk for severe COVID-19, as defined by the need for hospitalization or intensive care, include those with chronic cardiovascular or lung diseases, infants under 1 year of age, and immunocompromised patients receiving immunosuppression.

SARS-CoV-2 viral loads correlate with disease severity, as patients with severe disease have higher viral loads and longer decay times than those with mild or moderate symptoms. In contrast to viral dynamics, the immune response to SARS-CoV-2 remains undefined, though decreases in CD8+ T cells and B cells in adults have been correlated with severe COVID-19 and poor response to therapy, while CD8+ T cells and B cell recovery have been associated with moderate disease.

Decreases in regulatory T cells have also been linked with a hyperinflammatory response in adults, requiring the use of monoclonal blocking antibodies like tocilizumab, an antiinterleukin 6 (IL-6) agent. Interestingly, immune dysregulation and hyperinflammation as measured by whole blood transcription profiles have also been shown to correlate with severe respiratory syncytial virus (RSV) disease in infants, who also have higher viral loads and more protracted viral decay than infants with mild RSV. Similarly, reports are emerging that some children with COVID-19 are experiencing clinical symptoms and signs consistent with Kawasaki disease, a multisystem inflammatory disease of unclear etiology but often associated with respiratory viral infections.
TABLE 5 New approaches and directions for pediatric oncology following COVID-19

| Previous approach                      | New approach/direction                        |
|----------------------------------------|-----------------------------------------------|
| **Clinical**                           |                                               |
| Clinic visits                          | In-person visits                              |
| Workforce                              | In-person work week                           |
| **Research**                           |                                               |
| Site monitoring                        | In-person sponsor visits                      |
| Prioritization of new diagnostics and  | Conventional Food and Drug Administration (FDA) |
| therapeutics                           | review                                        |
| Database                               | Separate data collection and storage          |
| Protocol accommodations                | Administration of drug in hospital setting    |
| Government agencies                   | Visit to FDA and European Medicines Agency (EMA) |
| **Other**                              |                                               |
| Rechanneling efforts                  | Investigators physically met at institution or national/international meetings to share data |
| Collaborations                         | Competition among research groups             |

Despite their generally experiencing milder COVID-19, immunocompetent pediatric patients have high viral loads and may shed SARS-CoV-2 for weeks from the upper respiratory and lower gastrointestinal tracts after primary infection. This discrepancy between having milder COVID-19 despite having high viral loads and prolonged viral shedding suggests that children may differ from adults in their immune response to SARS-CoV-2. To this end, children and adults have defined differences in both innate and adaptive immune responses. As adults have a more proinflammatory background, they may be predisposed to more severe COVID-19 via a hyperinflammatory response to SARS-CoV-2.

Adults and children also differ in their immune response to viral challenge. Type I interferons (IFN) are key cytokines that have direct viral cytotoxic effects as well as immunomodulatory effects on both innate and adaptive immune cells. Deficits in type I IFN have been correlated with persistent viral load and exacerbated inflammatory response in adult patients with severe COVID-19. Interestingly, children with mild RSV disease (outpatient care) have recently been shown to have higher viral loads, greater induction of IFN genes, and decreased gene expression of inflammation and neutrophils versus children with severe RSV (inpatient care).

Taken together, epidemiologic and immunologic data on SARS-CoV-2 infection are emerging that may be helpful to explore why pediatric patients experience less severe COVID-19 and to implement potential therapies that would either augment helpful or inhibit harmful immune responses to SARS-CoV-2.

### 1.4 COVID-19 and pediatric cancer research: Potential avenues for common investigation

Our knowledge about antimicrobial and anticancer responses continues to evolve, as we gain understanding for their common inflammatory cellular and molecular pathways. For example, type I IFNs have direct antiviral effects but also have key roles in antitumor immunity. Furthermore, both cancer and infectious pathogens use similar strategies to avoid immune recognition. Finally, chronic inflammation and certain viral pathogens themselves promote oncogenesis. Therefore, immune profiling of SARS-CoV-2 infection may elucidate pathways involved in oncogenesis or inflammation that could be targeted with novel or repurposed cancer or supportive therapies.

Commonalities between antiviral and antitumor responses provide “silver linings” during the COVID-19 pandemic, given they could potentially foster and provide new directions for discovering therapies for cancer and COVID-19 (Table 4). For example, the BCR-ABL tyrosine kinase inhibitor, imatinib, revolutionized the treatment of Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL), such that allogeneic hematopoietic cell transplant in patients achieving molecular remission is no longer needed. Given its development as an ABL kinase inhibitor, imatinib has been shown to block coronavirus membrane fusion, inhibiting viral entry into cells. Similarly, the Janus kinase 1/2 inhibitor, ruxolitinib, and the blocking monoclonal IL-6 antibody, tocilizumab, may inhibit SARS-CoV-2-induced hyperinflammation in addition to their use in steroid-refractory graft-versus-host disease following allogeneic
hematopoietic cell transplant\textsuperscript{44} and cytokine storm following chimeric antigen receptor T cell therapy,\textsuperscript{45} respectively. Lastly, type I IFN, a key cytokine against viral infection and cancer,\textsuperscript{46} is being explored as a potential therapy against COVID-19.\textsuperscript{47}

Community respiratory viral infections are the most common type of infection in children. Given its high prevalence, high transmissibility, and lack of established therapeutic and preventative agents, SARS-CoV-2 will likely infect the majority of adults and children. Therefore, defining potential associations of SARS-CoV-2 with future cancer risk, especially in minority populations,\textsuperscript{48,49} seems warranted. As an example, in utero cytomegalovirus (CMV) infection has been associated with subsequent ALL risk (OR = 3.71, \( P = .0016 \)) most pronounced in Hispanics (OR = 5.90, \( P = .0006 \)) and hypothesized to occur given the supportive role of CMV in oncogenesis through induction of chromosomal instability and immune dysregulation.\textsuperscript{50} To be clear, no specific endemic coronaviruses have been linked to cancer risk and there is no a priori biologic reason to hypothesize an association with COVID-19. But observations seem prudent, especially as the immune response to SARS-CoV-2 remains undefined at this time.

In summary, mechanistic investigation into how SARS-CoV-2 induces different immune responses in various patient populations could provide invaluable insights for the fields of infectious disease and oncology research. Likewise, clinical and epidemiology exploration defining the role of SARS-CoV-2 and the influence of COVID-19 in other disease processes might also reveal roles for the virus not previously appreciated.

1.5 COVID-19 and pediatric oncology: Where do we go from here?

COVID-19 has impacted the entire world. Beyond its staggering toll on the health and survival of multitudes of people, COVID-19 will continue to impact many more millions of people, given the need to restructure life in response to an evolving pandemic. Adaptation to change requires flexibility in approaches for continuing pediatric oncology care and research, some of which may be carried forward given their potential longer term value as measured by improved efficiency, decreased burden to families, cost reduction, and ultimately new growth opportunities (Table 5).

The health crisis caused by COVID-19 warrants both scientific collaboration and reallocation of resources to contain its spread and to eradicate the disease entirely. However, other significant healthcare crises remain and potentially may be exacerbated by COVID-19, both directly by the virus itself or indirectly by the changes in life that the virus has caused. To this end, pediatric cancer remains the primary disease-related cause for mortality in children. Therefore, we must not lose focus on the need to continue to support, both scientifically and financially, research that is vital to discovering potential cures for pediatric cancer both to minimize the negative impact of COVID-19 and to leverage the lessons learned to make us better than before. Not fulfilling these missions jeopardizes the future of children with cancer, their families, and their communities.

ACKNOWLEDGMENTS

The authors would like to acknowledge all pediatric and adolescent and young adult (AYA) patients and families who have been touched by cancer and who inspire us as cancer clinicians and researchers and join us in the common pursuit in finding cures for all childhood cancers. We further acknowledge the additional layers of anxiety and complexity that COVID-19 has placed on them.

CONFLICT OF INTEREST

Peter C. Adamson is an employee of Sanofi, which is studying treatments for patients with COVID-19 infection including vaccines, sarilumab, and hydroxychloroquine. All other authors declare that there is no conflict of interest.

ORCID

Jeffery J. Auletta \( \text{https://orcid.org/0000-0002-1515-2141} \)

Peter C. Adamson \( \text{https://orcid.org/0000-0002-9487-757X} \)

REFERENCES

1. Solving Kids’ Cancer. The pandemic’s impact on the pediatric cancer research landscape. 2020. http://solvingkidscancer.org/covid19webinar/. Accessed April 28, 2020.
2. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541-52.
3. American Cancer Society. Cancer facts & figures 2020. https://www.cancer.org/cancer/cancer-in-children/key-statistics.html #references. Accessed April 26, 2020.
4. Yeh JM, Ward ZJ, Chaudhry A, et al. Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol. 2020;6(3):350-357.
5. World Health Organization. Coronavirus disease (COVID-2019) situation reports. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed May 6, 2020.
6. Van de Haar J, Hoes LR, Coles CE, et al. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020;26:665-671.
7. Cancer Research UK. COVID-19: open letter to cancer researchers. 2020. https://www.cancerresearchuk.org/funding-for-researchers/research-features/2020-04-06-covid-19-open-letter-to-cancer-researchers?utm_source=rbc_covid19_researcheropenletter. Accessed April 6, 2020.
8. Cancer Research UK. Cancer Research UK response to government’s charity package. 2020. https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2020-04-08-cancer-research-uk-respon e-to-governments-charity-package. Accessed April 8, 2020.
9. Excellence NIfHaC. COVID-19 rapid guideline: children and young people who are immunocompromised. 2020.
10. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 2020;145(5):e20200702.
11. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346.
12. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):pii2000547.
13. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with
coronavirus disease 2019 — United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-386.

14. CDC COVID-19 Response Team. Coronavirus disease 2019 in children—United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422-426.

15. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020. https://doi.org/10.1016/s1473-3099(20)30232-2.

16. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21(4):e181.

17. Thevarajan I, Nguyen THO, Koutsakos M, et al. Breath of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453-455.

18. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa248.

19. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-1034.

20. Mejias A, Dima B, Suarez NM, et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med. 2013;10:e1001549.

21. Garcia-Salido A. Three hypotheses about children COVID19. Pediatr Infect Dis J. 2020. https://www.researchgate.net/doi/pdf/3A%2F2P%2Fdoi.org/2%F10.1097%2FINF.0000000000002701.

22. Paediatric Intensive Care Society. PICS statement regarding novel presentation of multi-system inflammatory disease. Accessed April 27, 2020.

23. Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr. 2020. https://doi.org/10.1542/hpeds.2020-0123.

24. Turnier JL, Anderson MS, Heizer HR, Jone PN, Glode MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatrics. 2015;136:e609-e614.

25. Kam KQ, Yung CF, Cui L, et al. A well infant with coronavirus disease 2019 (COVID-19) with high viral load. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa201.

26. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502-505.

27. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity. 2012;37:771-783.

28. van den Broek T, Borghans JAM, van Wijk F. The full spectrum of human naïve T cells. Nat Rev Immunol. 2018;18:363-73.

29. Prendergast AJ, Klienerman P, Goulder PJ. The impact of differential antiviral immunity in children and adults. Nat Rev Immunol. 2012;12:636-648.

30. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15:87-103.

31. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12:125-35.

32. Hadjadj J, Yatin N, Barnabei L, et al. Impaired type I interferon activity and exacerbated inflammatory response to in severe COVID-19 patients. MedRxiv. 2020. https://doi.org/10.1101/2020.04.19.20068015.

33. Trouillet-Assant S, Viel S, Gaymard A, et al. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol. 2020. https://doi.org/10.1016/j.jaci.2020.04.029.

34. Heinenon S, Velazquez VM, Ye F, et al. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med. 2020;12(540):eaaw0268.

35. Tay MZ, Poh CM, Renia L, MacAray PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020. https://doi.org/10.1038/s41577-020-0311-8.

36. Goldszmid RS, Dzutsev A, Trinchieri G. Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe. 2014;15:295-305.

37. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759-771.

38. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405-414.

39. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97-111.

40. Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2012;2:98.

41. Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48:812-830, e14.

42. Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL031. Leukemia. 2014;28:1467-1471.

43. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol. 2018;99:619-630.

44. Martin PJ. How I treat steroid-refractory acute graft-versus-host disease. Blood. 2020;135(19):1630-1638.

45. Neelapu SS, Tummala S, Kebriaei P, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ‘ALL’. Nat Rev Clin Oncol. 2018;15:218.

46. Snell LM, McGaha TL, Brooks DG. Type I interferon in chronic virus infection and cancer. Trends Immunol. 2017;38:542-557.

47. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399.

48. Gold JA, Wong KK, Szablewki CM, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19—Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):545-550.

49. The IFS Deaton Review. Are some ethnic groups more vulnerable to COVID-19 than others? Institute for Fiscal Studies. May 1, 2020. https://www.ifs.org.uk/inequality/chapter/are-some-ethnic-groups-more-vulnerable-to-covid-19-than-others/. Accessed May 1, 2020.

50. Francis SS, Wallace AD, Wendt GA, et al. In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia. Blood. 2017;129:1680-1684.

How to cite this article: Auletta JJ, Adamson PC, Agin JE, et al. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer. 2020;67:e28435. https://doi.org/10.1002/pbc.28435